- Home
- PHVS vs HROW Comparison
PHVS vs HROW Comparison
Compare PHVS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- HROW
- Stock Information
- Founded
- PHVS 2015
- HROW 1998
- Country
- PHVS Netherlands
- HROW United States
- Employees
- PHVS N/A
- HROW N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- HROW Health Care
- Exchange
- PHVS Nasdaq
- HROW Nasdaq
- Market Cap
- PHVS 862.3M
- HROW 1.0B
- IPO Year
- PHVS 2021
- HROW N/A
- Fundamental
- Price
- PHVS $16.91
- HROW $22.24
- Analyst Decision
- PHVS Strong Buy
- HROW Strong Buy
- Analyst Count
- PHVS 5
- HROW 5
- Target Price
- PHVS $41.60
- HROW $55.40
- AVG Volume (30 Days)
- PHVS 50.2K
- HROW 379.9K
- Earning Date
- PHVS 05-07-2025
- HROW 03-17-2025
- Dividend Yield
- PHVS N/A
- HROW N/A
- EPS Growth
- PHVS N/A
- HROW N/A
- EPS
- PHVS N/A
- HROW N/A
- Revenue
- PHVS N/A
- HROW $169,138,000.00
- Revenue This Year
- PHVS N/A
- HROW $49.78
- Revenue Next Year
- PHVS N/A
- HROW $47.09
- P/E Ratio
- PHVS N/A
- HROW N/A
- Revenue Growth
- PHVS N/A
- HROW 48.15
- 52 Week Low
- PHVS $14.14
- HROW $9.30
- 52 Week High
- PHVS $26.57
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- PHVS 55.23
- HROW 26.17
- Support Level
- PHVS $14.49
- HROW $21.14
- Resistance Level
- PHVS $17.00
- HROW $24.00
- Average True Range (ATR)
- PHVS 1.32
- HROW 1.69
- MACD
- PHVS 0.18
- HROW -0.36
- Stochastic Oscillator
- PHVS 71.95
- HROW 13.85
Stock Price Comparison Chart: PHVS vs HROW
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.